London-based Oyster Therapeutics has unveiled $60 million to advance a preclinical program aimed at degrading pathological tau in Alzheimer’s disease and potentially other neurodegenerative disorders. The financing arrives as targeted protein degradation, already validated in oncology with the first degraders reaching the market this year, looks for ways to move beyond cancer and immunology into the brain.

Oyster’s central claim is that many degrader efforts have stalled not because the biology is uninteresting, but because the molecules are too large to function as practical brain medicines. CEO Rob Johnson said the first hurdle is intestinal absorption, followed by the separate challenge of crossing the blood-brain barrier. In that framing, the company is not just backing a tau hypothesis; it is trying to remove a delivery constraint that has shelved a number of degrader programs across biopharma.

The Technology Bet

A protein degrader is a heterobifunctional molecule, with one part binding the target protein and another binding the enzyme that marks that protein for degradation by the cell. That dual function makes degraders larger than many other small molecules.

Oyster says it addresses that size problem by designing a molecule that disassembles into two smaller molecules that can pass through biological membranes such as the intestinal wall and the blood-brain barrier. Johnson said those smaller molecules then reassemble inside a cell, including a neuron, to form the degrader that directs a disease-driving protein to the proteasome for elimination. He added that the chemistry behind the approach has been used in previously approved pharmaceuticals, while arguing Oyster is applying those chemical groups in a different way.

The commercial signal in that approach is broader than one Alzheimer’s asset. If the company can repeatedly turn a large degrader into a deliverable oral brain medicine, it would be tackling a platform-level bottleneck rather than making a one-off disease claim.

Why Tau, And Why Now

Johnson argued tau is well suited to a degrader approach because it does not have an active site where a classic small molecule inhibitor can bind. That has helped open the field to alternative modalities, including RNA medicines.

The source article points to two such competitors. Biogen’s diranersen, formerly BIIB0880, is an antisense oligonucleotide designed to bind the messenger RNA that carries instructions for making tau. In May, Biogen reported preliminary Phase 2 results showing reduction in tau and cognitive benefit in patients with Alzheimer’s, but the trial did not meet its main goal of showing a dose response according to a rating scale measurement at week 76. Biogen was scheduled to present new Phase 2 data this week during the Clinical Trials on Alzheimer’s Disease Conference in Boston. Arrowhead Pharmaceuticals is also in Phase 1/2 testing with ARO-MAPT, an siRNA therapy designed to silence the gene that codes for tau, and last month reported interim Phase 1/2 data showing reduced tau levels in healthy volunteers, with additional data expected in 2027.

Johnson’s critique of those approaches is selectivity. He said RNA drug candidates lower all tau, including healthy tau that is important for neuron function and found in high concentrations in the brain. By contrast, Oyster says its drug can selectively target an intermediary form of tau as the protein changes from healthy to pathological, while leaving healthy tau untouched.

The Strategic Case For An Oral Brain Degrader

Johnson also made a practical argument for modality choice. He said a small molecule is less expensive to manufacture than RNA medicines, stable at room temperature, and more convenient if given orally rather than by injection or infusion.

That matters most if Alzheimer’s treatment moves earlier. Johnson argued that in a pre-symptomatic patient population showing biological signs of disease but no symptoms, an injectable could be a difficult sell, while a safe oral option would be better positioned for broad access.

Oyster has not disclosed a Parkinson’s program, but Johnson said misfolded alpha-synuclein is the most obvious next neurological target for the SELFTAC platform. He also said the company’s degradation approach could apply to cancer, suggesting investors are backing a delivery concept with possible reach beyond neurodegeneration.